Barclays’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-2,000
| Closed | -$22K | – | 7509 |
|
|
2018
Q4 | $22K | Buy |
+2,000
| New | +$27.8K | ﹤0.01% | 5861 |
|
|
2018
Q2 | – | Sell |
-2,200
| Closed | -$40K | – | 7462 |
|
|
2018
Q1 | $40K | Sell |
2,200
-100
| -4% | -$1.67K | ﹤0.01% | 6063 |
|
|
2017
Q4 | $32K | Buy |
+2,300
| New | +$31.1K | ﹤0.01% | 6032 |
|
|
2017
Q1 | – | Sell |
-1,000
| Closed | -$15K | – | 7100 |
|
|
2016
Q4 | $15K | Buy |
+1,000
| New | +$13.2K | ﹤0.01% | 5758 |
|
|
2016
Q3 | – | Sell |
-100
| Closed | -$1K | – | 6898 |
|
|
2016
Q2 | $1K | Sell |
100
-1,000
| -91% | -$10.3K | ﹤0.01% | 6212 |
|
|
2016
Q1 | $10K | Buy |
1,100
+100
| +10% | +$1.08K | ﹤0.01% | 5485 |
|
|
2015
Q4 | $14K | Buy |
+1,000
| New | +$16.7K | ﹤0.01% | 5315 |
|
|
2015
Q3 | – | Sell |
-700
| Closed | -$15K | – | 7167 |
|
|
2015
Q2 | $15K | Sell |
700
-1,000
| -59% | -$19.9K | ﹤0.01% | 5858 |
|
|
2015
Q1 | $26K | Sell |
1,700
-300
| -15% | -$3.9K | ﹤0.01% | 5696 |
|
|
2014
Q4 | $24K | Sell |
2,000
-500
| -20% | -$5.71K | ﹤0.01% | 6228 |
|
|
2014
Q3 | $28K | Sell |
2,500
-8,300
| -77% | -$94.7K | ﹤0.01% | 6274 |
|
|
2014
Q2 | $130K | Buy |
10,800
+7,400
| +218% | +$87.4K | ﹤0.01% | 5214 |
|
|
2014
Q1 | $37K | Sell |
3,400
-14,900
| -81% | -$252K | ﹤0.01% | 6237 |
|
|
2013
Q4 | $311K | Sell |
18,300
-20,100
| -52% | -$338K | ﹤0.01% | 4560 |
|
|
2013
Q3 | $538K | Buy |
38,400
+9,600
| +33% | +$147K | ﹤0.01% | 4037 |
|
|
2013
Q2 | $434K | Buy |
+28,800
| New | +$380K | ﹤0.01% | 4383 |
|
Barclays's MNTA Position: Q4 2020 in Review
Barclays sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 248,815 shares — an estimated $13.1M sold.
Barclays first reported a position in MNTA in Q2 2013 and held it in 29 quarters. The position peaked at $13.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Barclays reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Barclays sold 248,815 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $13.1M.
- Barclays first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Barclays's Momenta Pharmaceuticals, Inc. position peaked at $13.1M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.